Clinical trials: Geriatric Disorders
COVID-19 Pneumonia, COVID-19
Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above
This is a open label clinical trial to evaluate the efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy people aged 3-17 years old in comparison with healthy population aged 18 years old…
- Trial name
- COVID-19 (NCT04917523)
- Testing
- SARS-CoV-2 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Cystic Fibrosis
A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor
This is a Phase 3, randomized, double-blind, ivacaftor-controlled, parallel-group, multicenter study of tezacaftor in combination with ivacaftor in subjects aged 12 years and older with CF who are heterozygous for the…
- Trial name
- NCT02412111
- Testing
- Ivacaftor, Tezacaftor/Ivacaftor
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 156 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Streptococcus Pneumoniae Vaccines
Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.
Streptococcus pneumoniae are bacteria which normally live in the upper respiratory tract of humans. However, these bacteria can also cause severe infectious diseases such as pneumonia, septicemia and meningitis.
- Trial name
- NCT00307008
- Testing
- Pneumovax 23™
- Where
- 5 sites in Sweden
- Volunteers
- 1,198 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Fabry Disease
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects > 12 Years of Age With Fabry Disease and Amenable GLA Variants
- Trial name
- NCT04049760
- Testing
- migalastat HCl 150 mg
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 16 people
- Sponsor
- Amicus Therapeutics
Skin Infections, Bacterial
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
- Trial name
- NCT00555061
- Testing
- Retapamulin Ointment, 1%
- Where
- 25 sites in United States, Argentina and 7 more
- Volunteers
- 60 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence, Stress
To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
The purpose of this study is to determine how effective duloxetine is in treating women who are 65 years of age or older with symptoms of stress urinary incontinence, or with a combination of stress urinary incontinence and urge…
- Trial name
- NCT00244296
- Testing
- Duloxetine hydrochloride
- Where
- 31 sites in France, Germany and 5 more
- Volunteers
- 276 people
- Sponsor
- Eli Lilly and Company
Epilepsy
Open Label Trial to Study the Long-term Safety and Efficacy of Seletracetam for the Treatment of Epilepsy
This is a safety and efficacy study of add-on therapy with seletracetam in epilepsy patients who have participated in a previous seletracetam study
- Trial name
- NCT00175851
- Testing
- Seletracetam (ucb 44212)
- Sponsor
- UCB Pharma
Influenza
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
The purpose of this study is to characterize the safety, immunogenicity, and relative efficacy of the H1N1 (swine) flu vaccines GSK2340273A and GSK2340274A in adults 18 years of age or older.
- Trial name
- NCT00979602
- Testing
- GSK2340274A, GSK2340273A
- Where
- 38 sites in United States, Canada
- Volunteers
- 4,048 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Epilepsy
A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
The purpose of this study is to evaluate the safety and tolerability of Fycompa (Perampanel) as an add-on therapy in epilepsy patients aged greater than or equal to 12 years.
- Trial name
- NCT02033902
- Testing
- Perampanel
- Where
- 42 sites in Austria, Belgium and 4 more
- Volunteers
- 500 people
- Sponsor
- Eisai Inc.
COVID-19
A Phase III Study of COVID-19 Vaccine EuCorVac-19 in Healthy Adults
This is a phase III, randomized, observer-blind, active-controlled, parallel group, multi-center study to compare the immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 to ChAdOx1 in healthy adults aged 18…
- Trial name
- NCT05572879
- Testing
- EuCorVac-19, ChAdOx1 nCoV-19
- Where
- Philippines
- Volunteers
- 2,600 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
COVID-19
Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
The purpose of this study is to evaluate the safety of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) after vaccination in people aged 18 and over.
- Trial name
- NCT06043388
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Influenza
Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational influenza vaccine GSK2340274A following one dose and following a second dose, using the same dosage as has been used in…
- Trial name
- NCT01001169
- Testing
- GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)
- Where
- Japan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vascular Cognitive Impairment no Dementia
Mexidol® Efficacy and Safety in Treatment of VCIND in Older Adults
The primary objective of this study is to evaluate the efficacy of Mexidol® sequential parenteral and oral administration as part of comprehensive therapy in older adults with chronic brain ischemia and vascular cognitive…
- Trial name
- NCT07700615
- Testing
- Mexidol, Standard Therapy
- Where
- 4 sites in Russia
- Volunteers
- 120 people
- Sponsor
- Pharmasoft
Cognition Disorders in Old Age
Study on the Effectiveness and Safety of Two Olive Extract- Based (Olea Europea L. Folium) Supplements, Alone or Combined With a Mullein Extract (Verbascum Thapsus L. Herba Cum Floribus), for the Maintenance of Cognitive Function.
The goal of this clinical trial is to learn if two food supplements based on olive leaf extract, alone or combined with mullein extract, help maintain cognitive function in older adults with mild cognitive impairment (MCI).
- Trial name
- NCT07586410
- Testing
- ACTIVE TREATMENT 1 - OLI-COGNITIVE FOOD SUPPLEMENT, ACTIVE TREATMENT 2 - OLI-VERB-COGNITIVE FOOD SUPPLEMENT
- Where
- Italy
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- ISTITUTO FARMOCHIMICO FITOTERAPICO: EPO SRL
Influenza
Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza
This study will evaluate the safety, pharmacokinetics and effectiveness of a single dose of 600 mg IV peramivir in the treatment of elderly subjects with acute uncomplicated influenza infection and in subjects with acute…
- Trial name
- NCT02635724
- Testing
- Peramivir
- Where
- 15 sites in United States
- Volunteers
- 74 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza, Swine-Origin A/H1N1 Influenza Virus
Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults
This study is designed to assess the safety of the approved and licensed HUMENZA (adjuvanted A/H1N1 pandemic influenza vaccine) and PANENZA (non-adjuvanted A/H1N1 pandemic influenza vaccine) to meet regulatory requirements for…
- Trial name
- NCT01032980
- Where
- 5 sites in France
- Volunteers
- 3,934 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
The purpose of the study is to determine how effective azacitidine, MGCD0103, and the combination of azacitidine and MGCD0103 are in treating AML or MDS in people over 60 years of age.
- Trial name
- NCT00666497
- Testing
- Azacitidine, MGCD0103
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 6 people
- Sponsor
- Mirati Therapeutics Inc.
Fecal Incontinence
Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of a Single Rectal Application of 10 mg NRL001 in Elderly Subjects
A total of 26 healthy elderly male and female subjects will receive both 10 mg NRL001 in a 2 g rectal suppository and placebo in this double-blind, cross-over study.
- Trial name
- NCT01099683
- Testing
- NRL001
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Norgine
Myopia
Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.
The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.
- Trial name
- NCT01917110
- Testing
- omafilcon A, Spectacle
- Where
- Spain
- Volunteers
- 79 people
- Sponsor
- CooperVision, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.